Autologous @entity2467 + Mesenchymal Stem Cell Injections Provide Superior Therapeutic Benefit as Compared to @entity2467 + Cardiac-Derived Stem Cells in a Feline Model of Isoproterenol-Induced XXXX .

@entity1603 @entity296 @entity13194 @entity2467
BACKGROUND: Cardiac- (CSC) and mesenchymal-derived (MSC) @entity2467 + isolated stem cells improve cardiac function after injury. However, no study has compared the therapeutic benefit of these cells when used autologously. METHODS: MSCs and CSCs were isolated on day 0. @entity296 was induced (day 28) by infusion of @entity13194 (1,100 ug/kg/hour) from Alzet minipumps for 10 days. @entity1603 ( @entity1603 ) was infused via minipumps (50 mg/mL) to identify proliferative cells during the injury phase. Following injury (day 38), autologous CSC (n = 7) and MSC (n = 4) were delivered by intracoronary injection. These animals were compared to those receiving sham injections by echocardiography, invasive hemodynamics, and immunohistochemistry. RESULTS: Fractional shortening improved with CSC (26.9    1.1% vs. 16.1    0.2%, p = 0.01) and MSC (25.1    0.2% vs. 12.1    0.5%, p = 0.01) as compared to shams. MSC were superior to CSC in improving left ventricle end-diastolic (LVED) volume (37.7    3.1% vs. 19.9    9.4%, p = 0.03) and ejection fraction (27.7    0.1% vs. 19.9    0.4%, p = 0.02). LVED pressure was less in MSC (6.3    1.3 mmHg) as compared to CSC (9.3    0.7 mmHg) and sham (13.3    0.7); p = 0.01. LV @entity1603 + myocytes were higher in MSC (0.17    0.03%) than CSC (0.09    0.01%) and sham (0.06    01%); p < 0.001. CONCLUSIONS: Both @entity2467 + isolated CSC and MSC therapy improve cardiac function and attenuate pathological remodeling. However, MSC appear to confer additional benefit.
